Drug Safety

Growing awareness of spondyloarthropathies over the last two decades has inevitably led to a better understanding of the pathophysiology of spondyloarthritis (SpA), and subsequently increased…

The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past…

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting. Study 144 pts Rx w/ Rituximab for Autoimmune renal Dz (AAV, FSGS, IgG4RD, LN, etc). 17% had Severe…

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like…